|
| |
Sinovac BiotechSinovac Biotech Ltd. (also known in China as Beijing Kexing Bioproducts) specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and “SARS”. Sinovac is one of the leading emerging biotechnology companies in China.
Working closely with Chinese public health officials, Sinovac focuses on manufacturing and marketing human-use vaccines and related products, and currently markets its vaccine for Hepatitis A. Sinovac is the first and currently the only company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS.
Recent Publications by Sinovac Biotech: |  |
Safety and immunogenicity of Sinovac's prototype pandemic influenza H5N1 vaccines: a review on clinical trials.
Sinovac Biotech started to develop prototype pandemic influenza H5N1... | 9th June, 2009
| Sinovac Biotech Co. Ltd, No. 39 Shangdi Western Road, Haidian District,
| Influenza Other Respi Viruses. 2008 Nov;2(6):237-42.
DOI Direct Link |
Preparation and characterization of SARS in-house reference antiserum.
A reference antiserum for SARS is in urgent need in the development of... | 8th February, 2006
| Sinovac Biotech Co. Ltd., No. 39, Shangdi Xi Road, Haidian District,
| Vaccine. 2005 Dec 1;23(48-49):5666-9. Epub 2005 Mar 16.
DOI Direct Link |
A serological survey on neutralizing antibody titer of SARS convalescent sera.
A seroepidemiologic study was conducted in North China in 2003 to... | 20th October, 2005
| Sinovac Biotech Co. Ltd., Beijing, China.
| J Med Virol. 2005 Oct;77(2):147-50.
DOI Direct Link |
Press Releases on Sinovac Biotech:
|
 |
| Sinovac to Present at Piper Jaffray Health Care Conference |
24th November, 2009 |
Sinovac Biotech, Ltd. |
BEIJING, Nov. 24 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA),
a leading provider of biopharmaceutical products in China, announced today
that management is scheduled to present at the
|
| Sinovac Files Shelf Registration Statement |
18th November, 2009 |
Sinovac Biotech Ltd. |
BEIJING, Nov. 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA),
a leading developer and provider of vaccines, announced today that it has
filed a shelf registration statement on Form F-3
|
| Sinovac's PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population |
17th November, 2009 |
Sinovac Biotech Ltd. |
BEIJING, Nov. 17 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA),
a leading developer and provider of vaccines in China, announced today that it
received a revised production license from
|
| Sinovac Reports Unaudited Third Quarter 2009 Financial Results |
15th November, 2009 |
Sinovac Biotech Co., Ltd. |
-- Cash and cash equivalents at September 30, 2009 was $46.6 million.
Business Highlights
-- In August, Sinovac reported positive top-line results from the completed
clinical
|
| Sinovac to Host Conference Call to Report 2009 Third Quarter Financial Results |
10th November, 2009 |
Sinovac Biotech Ltd. |
BEIJING, Nov. 10 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.
(NYSE Amex: SVA), a leading provider of vaccines in China, today announced
that it will host a conference call on Monday, November 16,
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 476 times since April 2007, the link to the organisation's website has been followed 63 times Recent Search Terms used to find this page: Clinical Trial With Influenza A H1N1 Vaccines | sinovac biotec | sinovac logo | sinovac logo | view of sinovac biotech pharmaceutical | sinovac biotec nyse | SINOVAC LOGO | sinovac biotech | elan sinovac | sinovac biotech | . This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Sinovac Biotech |
